These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 26680454)

  • 41. [BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].
    Lopes JP; Fonseca E
    Acta Med Port; 2011 Dec; 24 Suppl 4():855-68. PubMed ID: 22863493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinomas.
    Schulten HJ; Alotibi R; Al-Ahmadi A; Ata M; Karim S; Huwait E; Gari M; Al-Ghamdi K; Al-Mashat F; Al-Hamour O; Al-Qahtani MH; Al-Maghrabi J
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S6. PubMed ID: 25922907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diallyl trisulphide, a H
    Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
    Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
    Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
    Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene expression profile of human thyroid cancer in relation to its mutational status.
    Rusinek D; Szpak-Ulczok S; Jarzab B
    J Mol Endocrinol; 2011 Dec; 47(3):R91-103. PubMed ID: 21798995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer.
    Saini S; Maker AV; Burman KD; Prabhakar BS
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188262. PubMed ID: 30605717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response to RET-Specific Therapy in
    Dias-Santagata D; Lennerz JK; Sadow PM; Frazier RP; Govinda Raju S; Henry D; Chung T; Kherani J; Rothenberg SM; Wirth LJ
    Thyroid; 2020 Sep; 30(9):1384-1389. PubMed ID: 32292131
    [No Abstract]   [Full Text] [Related]  

  • 49. The Role of miRNA in Papillary Thyroid Cancer in the Context of miRNA Let-7 Family.
    Perdas E; Stawski R; Nowak D; Zubrzycka M
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
    Lee JJ; Foukakis T; Hashemi J; Grimelius L; Heldin NE; Wallin G; Rudduck C; Lui WO; Höög A; Larsson C
    Thyroid; 2007 Apr; 17(4):289-301. PubMed ID: 17465858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circulating BRAF
    Lubitz CC; Zhan T; Gunda V; Amin S; Gigliotti BJ; Fingeret AL; Holm TM; Wachtel H; Sadow PM; Wirth LJ; Sullivan RJ; Panka DJ; Parangi S
    Thyroid; 2018 Mar; 28(3):328-339. PubMed ID: 29378474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
    Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
    In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?
    Volante M; Lam AK; Papotti M; Tallini G
    Endocr Pathol; 2021 Mar; 32(1):63-76. PubMed ID: 33543394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid.
    Schulten HJ; Al-Mansouri Z; Baghallab I; Bagatian N; Subhi O; Karim S; Al-Aradati H; Al-Mutawa A; Johary A; Meccawy AA; Al-Ghamdi K; Al-Hamour O; Al-Qahtani MH; Al-Maghrabi J
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S7. PubMed ID: 25923053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status.
    Tsuchida N; Ikeda MA; Ιshino Υ; Grieco M; Vecchio G
    Int J Oncol; 2017 Jun; 50(6):2043-2048. PubMed ID: 28440416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
    Ibrahimpasic T; Ghossein R; Shah JP; Ganly I
    Thyroid; 2019 Mar; 29(3):311-321. PubMed ID: 30747050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.